We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Concord Medical Opens Datong Meizhongjiahe Cancer Hospital

By HospiMedica International staff writers
Posted on 07 Jun 2016
Print article
Image: The Concord Cancer Hospital in Guangzhou, China (Photo courtesy of Concord Medical Services).
Image: The Concord Cancer Hospital in Guangzhou, China (Photo courtesy of Concord Medical Services).
Concord Medical Services (CMS, Beijing, China) has announced the preliminary opening of Datong Meizhongjiahe Cancer Hospital (Shanxi Province, China).

The 100-bed hospital is a Level-II specialty cancer hospital with radiation, imaging, test laboratory, radiotherapy, and diagnostic imaging equipment, including a linear accelerator and a magnetic resonance imaging (MRI) system. The hospital is the first wholly owned hospital in the projected Meizhongjiahe-branded network of hospitals planned for Chinese Tier II and Tier III cities, and will complement CMS high-end hospitals in Tier I cities such as Beijing, Shanghai, and Guangzhou.

As of December 31, 2015, CMS operated a network of 127 centers with 76 hospital partners that spanned 53 cities and 25 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients.

“We are very pleased to celebrate the transformative milestone in the history of Concord Medical. This first wholly-owned domestic cancer hospital in China is an important step of our broad strategy to build a nationwide chain of free-standing cancer treatment and diagnosis centers under the brand ‘Meizhongjiahe’ in the future,” said Jianyu Yang, MD, chairman and CEO of CMS. “There is strong patient demand in Tier II and Tier III cities in China for advanced cancer diagnosis and treatments, and we see their challenge as ours.”

CMS is undergoing an expansion drive in the Chinese domestic market, and is currently establishing specialty cancer hospitals in Wuxi, Hangzhou, Taizhou, and Nanchang. In addition, as part of its high-end cancer hospital development strategy and oversea business extension, the company acquired Concord Cancer Hospital, a private hospital in Singapore in April 2015.

Related Links:
Concord Medical Services

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Instrument Table
Flexible and Rotatable 10-066
New
Surgical Operating Lamp
OKM 600E

Print article

Channels

Surgical Techniques

view channel
Image: Graphical abstract; Surgical field during endomyocardial biopsy and fluoroscopic images (Photo courtesy of Heart Rhythm, DOI: 10.1016/j.hrthm.2024.10.069)

Novel Method Combining Heart Biopsy and Device Implantation Reduces Complications Risk

Endomyocardial biopsy (EMB) is a crucial diagnostic tool for identifying various cardiac conditions; however, it carries a risk of complications due to its invasive nature. New research has introduced... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.